BICO has been awarded this year's SwedenBIO Award for showcasing the power of the Swedish life-science industry on the global arena and its visionary business model and remarkable growth
The world-leading bio convergence company, BICO, today announced that it has received SwedenBIO's Award which was announced in connection with SwedenBIO's Annual Summit in Stockholm. Presented for the last fifteen years, the Award honors a life-science company that has shown outstanding achievements and contributions to society and that exemplifies the potential of a strong Swedish life science industry.
"We are incredibly honored to receive this award from SwedenBIO, an important and respected industry player," says Erik Gatenholm, CEO and co-founder of BICO. "I am humbled and look forward to continue to develop our offering and contribute to enabling Health 4.0."
SwedenBIO is one of Europe´s largest industry organizations representing more than 300 member companies in Sweden. SwedenBIO is the industry´s only national organization with a mission to promote an environment bringing success and growth to the entire Swedish life science industry.
”BICO has contributed to the good repute of the Swedish life-science industry internationally and shown what can be achieved with a bold approach to market expansion. By presenting them with the SwedenBIO Award, we hope that BICO can inspire Swedish companies as they strive to take market shares in their respective areas,” said Mårten Steen, Managing Partner at HealthCap, who handed out the award onstage at the summit.
the distinction of the award, a floating trophy that changes hands annually with each new champion, and attendance at Nordic Life Science Days in Malmö in April 2022.
Founded in 2016, BICO has quickly grown from being one company focused on bioinks and bioprinters to a global cohesive group of thirteen companies with an extensive range of bio convergence products and solutions enabling Health 4.0. BICO focuses on four Next Generation Core industrial eco systems; Tissue Engineering, Diagnostics, Multiomics and Cell Line Development.
For more information on SwedenBIO, please visit: www.swedenbio.se
For further information, please contact:
BICO Press office Sweden
Hedda Söderström, Communications Manager: + 46 73 509 2261
BICO Press office US
Riley Munks, PR Manager: (650) 863-6699
Alyssa D’Orazio, PR Manager: (617) 634-9601
This information was submitted for publication, through the agency of the contact persons set out above, on December 8, 2021, at 5.30 pm (CET).
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO's technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com